SAN FRANCISCO — Max Hodak's Science Corporation just closed a $230 million Series C round at a $1.5 billion valuation, betting that the market for implantable brain-computer interfaces will eventually grow beyond niche medical applications.
The neural engineering firm's flagship product, PRIMA, has already restored sight to patients with severe vision loss using a biohybrid approach: a camera-equipped headset beams captured images to a chip implanted in the retina. The company is now expanding into seizure prediction, Parkinson's treatment, and cognitive enhancement—a diversified application strategy designed to hedge against any single indication failing clinical trials or facing regulatory rejection.
The valuation math assumes meaningful market size. Vision restoration alone is addressable but limited—perhaps tens of thousands of patients globally with advanced retinal degeneration willing to undergo surgery. Neurological conditions like Parkinson's or epilepsy offer larger addressable markets, but establishing reimbursement from Medicare or private insurers for an implantable device remains harder than most founders acknowledge. The company hasn't disclosed pricing, reimbursement pathways, or timelines to commercialization beyond the vision product.
Hodak, a Neuralink co-founder, has credibility in deep tech execution. His earlier company, Transcriptic, built robotic cloud labs for biotech research before being acquired by Benchling in 2022. That track record matters: neural engineering is genuinely hard, and most startups in this space have failed to move beyond animal models or small human cohorts.
Science Corp's competitive moat, if it exists, rests on manufacturing expertise and regulatory precedent. PRIMA's early human success gives the company years of head start over well-funded competitors like Synchron and Neuralink itself. But the sector remains pre-scale: total addressable market estimates are speculative, and reimbursement models are undefined.
The $1.5 billion valuation prices in massive optionality. For that bet to pay off, Hodak needs to either expand PRIMA into a mainstream vision-loss treatment with durable reimbursement, or prove that neural implants can address broader cognitive or movement disorders at scale. Neither is assured. The capital raise buys runway for multi-year human trials and regulatory approval processes, but the path from implant to profitable unit economics remains unproven.
